Talphera CEO Vince Angotti confirmed that the company has finished realigning its clinical sites, ensuring all target locations are now active. This operational milestone aligns with a favorable shift in the regulatory landscape, as the 2026 KDIGO guidelines now recognize nafamostat as an acceptable anticoagulant for continuous renal replacement therapy. This update represents a distinct change from prior clinical recommendations and strengthens the potential commercial path for the company’s lead candidate, Niyad.

Financially, the company reported a cash and investment balance of $17.1 million as of June 30, 2026. The net loss for the second quarter reached $4.3 million, compared to $3.5 million during the same period last year, a variance primarily driven by higher development expenses associated with the ongoing trial. Talphera recently regained compliance with Nasdaq’s $1 minimum bid price rule and plans to host an investor event to discuss future commercial opportunities as trial enrollment nears its final phase.